Partnership Opportunities

Why Partner With Us?

The LAG-3 Targeted Drug Development Summit industry specific focus makes it the main platform for bringing together the decision makers in immune-oncology. This is your opportunity to get the message out about your products and services, elevate your brand and demonstrate your expertise in this growing field. Register your interest for the 2023 program.

Partnership opportunities will enable you to: 

HW210909_LAG-3_Targeted_Drug_Development_Summit_Logo_ICON-removebg-preview
HW210909_LAG-3_Targeted_Drug_Development_Summit_Logo_ICON-removebg-preview
HW210909_LAG-3_Targeted_Drug_Development_Summit_Logo_ICON-removebg-preview
HW210909_LAG-3_Targeted_Drug_Development_Summit_Logo_ICON-removebg-preview

Accelerate and support clinical development, whilst positioning yourself as the leading CRO in this space

Share what your PDX, syngeneic and humanized models offer to improve the quality of preclinical research, critical to the timely advancement of these novel therapeutics

Showcase your capabilities to boost the early development of immune-oncology therapies

Display your regulatory expertise to support developers in their efforts

Get in Touch to Find Out More About Partnership Opportunities

Thomas Vickers

Thomas Vickers 
Partnership Director

Email: sponsor@hansonwade.com
Phone: +1 617 455 4188